Post by
managementfirst on Mar 28, 2024 2:40pm
Is she saying that TLT can get fund rather than PP in 2024?
Kristina Hachey CPA, Chief Financial Officer of Theralase® stated, "The 2023 annual financial statements are representative of the Company investing in the development of its lead asset, light-activated RuvidarTM, with a focus on commercializing the next standard of care treatment for BCG-Unresponsive NMIBC CIS. In 2024, the Company plans to secure funding through various equity and debt instruments to allow the Company the ability to become base shelf eligible. This will allow the Company sufficient funding to complete enrollment into Study II by year end, data lock in mid 2026 and position the Company for FDA and Health Canada approval the end of 2026."
Comment by
DeathXray33 on Mar 28, 2024 2:56pm
"commercializing", "standard of care", "equity and debt instruments", "sufficient funding"...
Comment by
Legit62 on Mar 28, 2024 3:12pm
Sounds to me like PPs are thing of the past, off to bigger and better pastures from the sound of that statement, could be wrong, have been wrong before but we are getting close and they are surely looking for the big hit
Comment by
StevenBirch on Mar 28, 2024 3:33pm
After the one we are going through right now. Hopefully these Advisory Board Meetings are really going to kickstart things.
Comment by
Rumpl3StiltSkin on Mar 28, 2024 6:48pm
Yep Legit, They likely realise more PPs aren't a good look moving towards BTD and partnerships, IMO.
Comment by
riverrrow on Mar 28, 2024 7:05pm
A few days ago posters were saying there is a pp underway. Is that off the table? And where is Roger?
Comment by
O12009 on Mar 28, 2024 7:29pm
We will all find out April 3 at 11 am ET. The zoom call will answer a lot of questions.
Comment by
Donein25 on Mar 28, 2024 7:46pm
I would expect a PR at 7am Wednesday. We have never had a conference call/ Zoom meeting announced after a financial release, until now. Heck we don't even get Zoom calls for AGMs (despite my pleas in the past). Something must be coming.... my guess is a debt offering,or maybe less likely another shot at a public offering.
Comment by
Rumpl3StiltSkin on Mar 29, 2024 10:05am
River, I think that another pp is possible. Yet, they do seem to be working on other ways. Which is incouraging.
Comment by
Eoganacht on Mar 29, 2024 2:20pm
If Theralase finds an alternate means of funding will this dis-incentivize those who are driving the sp down.
Comment by
Legit62 on Mar 29, 2024 2:39pm
My thought is once we get BTD and AA and start to get some bigger investors involved once we are derisked the shorters will disappear cause there will be higher volume trades with more bids and we should shoot up, but until then the games continue, if you look at the miniscule volume causing this SP to go lower its a joke
Comment by
Oilminerdeluxe on Mar 29, 2024 3:26pm
Perhaps the video meeting will shed some laser light on things.
Comment by
gonefishing2022 on Mar 29, 2024 8:38pm
The Shorters will always be here
Comment by
Rumpl3StiltSkin on Mar 30, 2024 12:27pm
Eoga, Yes. I think so. They need to right size the debt so that they have a nice runway to get past BTD and any partner/regional deals they are negotiating. Would also be nice if they get enough to complete the GLP for solid tumors. This debt will add to cash burn but if they get enough to last a cpl/few years??? IMO And it 'should' take the lid off this stock price.
Comment by
Infinity on Mar 28, 2024 9:10pm
I think we are headed toward another PP. Debt is not their preferred option so far